Interviews with and commentary from experts and innovators in hematology.
ASH Annual Meeting
Is Rivaroxaban Safe as Long-Term Prevention for Deep-Vein Thrombosis?
Multiple Advances in Multiple Myeloma
What Was Hot at ASH 2015?
Rivaroxaban in Cancer-Associated VTE: Results from CALLISTO
Late-Breaking Abstract: RESONATE 2 Finds First-Line Ibrutinib Superior to Chlorambucil in CLL/SLL
The Balancing Act of Caring for Older Patients with Hemophilia
Ibrutinib Beats Temsirolimus in Relapsed/Refractory MCL
Improving Quality of VTE Care
The PROs of Patient-Reported Outcomes
Induction Chemotherapy for AML: Understanding the Patient Experience
Late-Breaking Abstract: First-in-Man Trial of CAR T Cells in Myeloma
Ixazomib Extends PFS in the TOURMALINE-MM1 Trial
Evolving Issues in Anticoagulation
Predicting Prognosis in Myelodysplastic Syndromes
New Approaches in CLL and Prolymphocytic Leukemia
Late-Breaking Abstract: Eltrombopag Improves Response in Severe Aplastic Anemia
Optimizing Therapy in Sickle Cell Disease
Controversy over Quality
Eligibility Criteria Not Associated with Adverse Events in RCTs
Newly Approved Drugs: How Should We Use Them in the Clinic?
Guiding Hematologic Care with Genetic Testing
ASH Meeting on Hematologic Malignancies
Ruben A. Mesa, MD: Treating Myelofibrosis After Ruxolitinib “Failure”
Melissa A. Crawley, MD: How Can We Enroll More Young Patients in Clinical Trials?
Jennifer R. Brown, MD, PhD: Ibrutinib and Atrial Fibrillation Risk in RCTs
Aziz Nazha, MD: How Do TP53 Mutation Characteristics Affect MDS Outcomes?
Jonathan Friedberg, MD: Treating Highly Aggressive Lymphomas
Joseph M. Connors, MD: Optimizing Therapy, Minimizing Toxicity in Hodgkin Lymphoma
Hetty Caraway, MD: Improving Classification in High-Grade MDS
Bhagirathbhai Dholaria, MBBS: Overlapping Myeloma and CLL: Double Trouble?
Jennifer R. Brown, MD, PhD: The Changing Definition of “High-Risk” CLL
Brad Schenkel, MSc: Predicting Hospitalizations, ER Visits Among CLL Patients
Jaleh Fallah, MD: Is the Combo of Abbreviated Chemo Plus Radiation Therapy a Viable Option for DLBCL Patients?
Asher Alban Chanan-Khan, MD: Ibrutinib + Bendamustine/Rituximab in Patients with Previously Treated CLL/SLL
Ksenia Romanova, MD: Age, Sex, Timing of Treatment Predict Avascular Necroses in Children with ALL
Collaborative Care Delivery Reduces Travel Burden for AML Patients
Highlights of the 2015 ASH Meeting on Hematologic Malignancies
HIV-Associated Lymphoma: Treatment Patterns and Survival in the Antiretroviral Era
The Future of Clinical and Translational Research in Hematologic Malignancies
Daratumumab Safe in Relapsed/Refractory Multiple Myeloma Patients
Ixazomib Benefit Persists Despite Prior Therapy in TOURMALINE-MM1 Subset Analysis
Venetoclax Plus Hypomethylating Agents Leads to High Response Rates in Older Patients with AML
COMFORT: Five-Year Outcomes of Ruxolitinib in Patients With Myelofibrosis
CPX-351: A Potential Game-Changer for Older Patients With Newly Diagnosed Secondary AML?
Study Finds Thrombosis Risk Changes Throughout Myeloma Disease Course
Mogamulizumab May Be Effective in Relapsed/Refractory T-Cell Leukemia
SL-401: An Encouraging Option for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm
CASTOR Trial: Daratumumab Combination Doubles Response Rates in Myeloma Patients
TOURMALINE-MM3 and 4: Ixazomib as Maintenance Therapy in Myeloma Patients
For Older AML Patients, Venetoclax With Low-Dose Cytarabine is Safe and “Promising”
Bortezomib Leads to More Complete Remissions in Patients With High-Risk Follicular Lymphoma
Ixazomib Plus Pomalidomide, Dexamethasone in Relapsed/Refractory Myeloma
Optimizing CAR T-Cell Therapy in Relapsed/Refractory ALL
ASP2215 Successfully Inhibits FLT3 in High-Risk AML Patients
SIRIUS: Promising Results for Daratumumab in Hard-to-Treat Myeloma Patients
Ruxolitinib in CMML: Study Shows Promising Results
Options for Treating the High-Risk APL Patient
PERSIST-1: Pacritinib Shakes Up the Current Myelofibrosis Treatment Landscape